The shareholders of Evolva Holding AG approved the sale of Evolva AG to Danstar Ferment AG, a Swiss affiliate of Lallemand Inc., for CHF 20 million – on December 21. One week later, the parties closed the transaction. Evolva Holding SA will seek the delisting of its shares from SIX Swiss Exchange and expects the delisting to take place after a customary period of 6-12 months.

The liquidation of the company is currently expected to be completed in the first quarter of 2026.

Stephan Schindler, Chairman of Evolva Holding SA, comments: “We thank the Evolva shareholders for their support to enable the transaction with Lallemand, securing the future of Evolva AG’s operations for its employees, customers and partners. Our focus is now on the orderly handling of the liquidation of the Company, considering potential earn-out payments and the distribution of a respective liquidation dividend.”

Evolva is a Swiss biotech company focused on the research, development and commercialization of ingredients based on nature. It focuses on Flavors and Fragrances, Health Ingredients and Health Protection.

Photo: Pexels (#1153369)